Risk of Guillain-Barré syndrome following serogroup C meningococcal conjugate vaccine in Quebec, Canada.
To assess the risk of Guillain-Barré syndrome (GBS) following administration of meningococcal serogroup C-CRM(197) conjugate vaccine, provincial immunization records were linked with hospital discharge records, and medical charts were reviewed. In the cohort of 1.9 million individuals (age, 2 months to 20 years), observed postvaccination frequencies of GBS were not higher than expected.
De Wals
Philippe
P
Department of Social and Preventive Medicine, Laval University, Quebec City, Canada. Philippe.De.Wals@ssss.gouv.qc.ca
Deceuninck
Geneviève
G
Boucher
Renée-Myriam
RM
Ouakki
Manale
M
D000293:Adolescent; D000328:Adult; D002648:Child; D002675:Child, Preschool; D015331:Cohort Studies; D020275:Guillain-Barre Syndrome / Q000175:diagnosis / Q000453:epidemiology* / Q000209:etiology; D006801:Humans; D007223:Infant; D022401:Meningococcal Vaccines / Q000008:administration & dosage* / Q000009:adverse effects; D011792:Quebec / Q000453:epidemiology
D022401:Meningococcal Vaccines; C410218:serogroup C meningococcal conjugate vaccine